Updated:
HS LifeSciences
HS LifeSciences is a venture capital investor focused on life sciences opportunities. The firm invests in life science spin-outs from European and North...
HS LifeSciences
HS LifeSciences is a venture capital investor focused on life sciences opportunities. The firm invests in life science spin-outs from European and North American research institutions. It supports new life science companies by providing management, financial, and commercial expertise.
General information
Firm type
Private Equity
Year founded
2015
Location
Region
Europe
Country
Germany
City
Düsseldorf
Corporate office
Düsseldorf, Germany
Principals
Dr. Gunnar Weikert
Founder and Managing Partner
Dr. Kristian Rettig
Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at HS LifeSciences?
Founder and Managing Partner Dr. Gunnar Weikert and Managing Partner Dr. Kristian Rettig share final investment authority, per the firm's official communications. Both are physicians by training. They are supported by a scientific advisory board of external clinicians who participate in due diligence.
How does HS LifeSciences source its deals?
The firm leans heavily on its network of practicing physicians, academic medical centers, and European research institutions for proprietary deal flow. Its managing partners' clinical backgrounds and the firm's scientific advisory board give it early visibility into science emerging from university labs and teaching hospitals.
What is HS LifeSciences' known posture on co-investments alongside external GPs?
HS LifeSciences co-invests with specialist healthcare investors and generalist venture firms. It seeks to attract co-investors who can add clinical or regulatory expertise, not just capital. The firm has syndicated rounds with international life-science VCs and corporate venture arms.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: